Standing on Principal

12/30/2010

ValueAct Capital's Jeffrey Ubben describes how he hedges without shorting, why he may take 18 months to build a core investment, why he expects M&A activity to take off in the coming year, why he resists the “macro” fetish, and why he sees unrecognized value in Willis Group, VeriSign, Valeant Pharmaceuticals, C.R. Bard and Misys.


If you are a subscriber, log in to access the issue and bonus archive:


Not a subscriber? Subscribe today!